Moderna has become the second company to get emergency use authorisation for its anti-coronavirus vaccine from the US Food and Drug Administration (FDA), a week after the one developed by Pfizer received a similar approval.
According to an official statement, the FDA has determined that the Moderna COVID-19 vaccine has met the statutory criteria for issuance of an emergency use authorisation (EUA).
“Congratulations, the Moderna vaccine is now available!” President Donald Trump tweeted soon after.
The FDA based its recommendation on the totality of scientific evidence shared by Moderna, including a data analysis from the pivotal phase three clinical study announced on November 30. The primary efficacy analysis conducted on 196 cases indicated a vaccine efficacy rate of 94.1 per cent.
This vaccine is for people aged 18 or older.
An immunisation drive using the vaccine developed by Pfizer has begun in the US earlier this week. Vice President Mike Pence took the shot publicly on Friday.